All In Biotech

Drug Trial Radar · NCT04588311

ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients

A Randomised, Double-blind, Placebo-controlled Trial of Erythropoietin Alfa Versus Placebo in Mechanically Ventilated Critically Ill Patients Following Traumatic Injury

Last checked: Nov 20, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,500

Planned (sponsor's estimate)

Start

Nov 9, 2020

Primary completion

Dec 31, 2026

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Australian and New Zealand Intensive Care Research CentreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University College Dublin; Medical Research Institute of New Zealand; Medical Research Future Fund; Health Research Board, Ireland; Health Research Council, New Zealand; Irish Critical Care Clinical Trials Network; ANZICS Clinical Trials Group; Monash University
First posted
Oct 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The EPO-TRAUMA study is a prospective, multi-centre, double-blind, phase III, randomised controlled trial evaluating the efficacy of epoetin alfa compared to placebo in reducing mortality and severe disability at six months in critically ill trauma patients. 2500 mechanically ventilated ICU patients admitted with a primary trauma diagnosis presenting to the ICU will be recruited into the study from participating study centres in Australia, New Zealand, Europe, and Saudi Arabia.

Conditions

  • Trauma
  • Traumatic Injury
  • Traumatic Brain Injury
  • Wounds and Injuries
  • Penetrating Injury
  • Blunt Injury
  • Major Trauma
  • Multiple Trauma

Interventions

  • Epoetin Alfa 40000 UNT/MLDrug

    Epoetin alfa 40,000IU 1mL pre-filled syringe given as subcutaneous injection.

  • Sodium Chloride 0.9%Drug

    Sodium Chloride 0.9% 1mL in volume given as subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Combined proportion of participants who have died or have severe disability (WHODAS 2.0 > 25)Time frame: 6-months

Locations

41 sites in 9 countries. Site status is shown where the registry gives one.

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia · Recruiting

  • St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, Australia · Active not recruiting

  • St George Hospital

    Kogarah, New South Wales, Australia · Recruiting

  • Liverpool Hospital

    Liverpool, New South Wales, Australia · Recruiting

  • John Hunter Hospital

    New Lambton Heights, New South Wales, Australia · Recruiting

  • Royal North Shore Hospital

    Saint Leonards, New South Wales, Australia · Recruiting

  • Westmead Hospital

    Westmead, New South Wales, Australia · Recruiting

  • Royal Darwin Hospital

    Tiwi, Northern Territory, Australia · Not yet recruiting

  • Cairns Hospital

    Cairns, Queensland, Australia · Withdrawn

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia · Recruiting

  • Gold Coast University Hospital

    Southport, Queensland, Australia · Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia · Recruiting

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia · Recruiting

  • Flinders Medical Centre

    Adelaide, South Australia, Australia · Not yet recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Royal Melbourne Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Royal Perth Hospital

    Perth, Western Australia, Australia · Recruiting

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium · Not yet recruiting

  • HUB Hopital Erasme

    Brussels, Belgium · Not yet recruiting

  • CHU-Charleroi Chimay

    Charleroi, Belgium · Recruiting

  • Ziekenhuis Oost-Limburg

    Genk, Belgium · Not yet recruiting

  • Ghent University Hospital

    Ghent, Belgium · Not yet recruiting

  • CHR de la Citadelle de LIEGE

    Liège, Belgium · Not yet recruiting

  • Helsinki University Hospital (HUS)

    Helsinki, Finland · Recruiting

  • Kuopio University Hospital

    Kuopio, Finland · Recruiting

  • Turku University Hospital

    Turku, Finland · Recruiting

  • University Hospital Münster

    Münster, Germany · Recruiting

  • Beaumont Hospital

    Beaumont, Ireland · Recruiting

  • Cork University Hospital

    Cork, Ireland · Recruiting

  • St Vincent's University Hospital

    Dublin, Ireland · Recruiting

  • Auckland City Hospital

    Grafton, Auckland, New Zealand · Recruiting

  • Christchurch Hospital

    Christchurch, Christchurch, New Zealand · Recruiting

  • Middlemore Hospital

    Auckland, Otahuhu, New Zealand · Recruiting

  • Waikato Hospital

    Hamilton, Waikato Region, New Zealand · Recruiting

  • Wellington Hospital

    Newtown, Wellington Region, New Zealand · Recruiting

  • King Abdulaziz Medical City

    Riyadh, Saudi Arabia · Recruiting

  • University Medical Centre Ljubljana

    Ljubljana, Slovenia · Recruiting

  • University Medical Centre Maribor

    Maribor, Slovenia · Recruiting

  • University Hospital Bern

    Bern, Switzerland · Recruiting

  • Lucerne Cantonal Hospital

    Lucerne, Switzerland · Not yet recruiting

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.